Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).
published in: British Journal of Dermatology
date of publication: 2015-09-10
language: English
main subject: phase III clinical trial, plaque psoriasis
Cites articles
There is nothing here
Article - wd:Q41006571